Xtant Medical Holdings Inc (XTNT)
Official siteHEALTHCARE • MEDICAL DEVICES • AMEX
Market Cap: $38.12M
Last updated: Nov 17, 2026 at 4:10 PM ET
Xtant Medical Holdings Inc (XTNT) Stock Chart
Xtant Medical Holdings (XTNT) has a latest price of $0.20 on Nov 17, 2026, 75.9% below its 52-week high of $0.84. Its price fell 68.9% over the past 12 months. The month-end price fell 96.9% over the 10 years through Oct 2026, a compound annual decline of 29.3%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $9.00 in Oct 2016 and its lowest $0.28 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart XTNT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for XTNT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 38.6%, and over 6 months it fell 55.9%. The month-end price fell 76.1% over the 3 years through Oct 2026, a compound annual decline of 37.9%.
| Period | Change |
|---|---|
| 1 month | -30.4% |
| 3 months | -38.6% |
| 6 months | -55.9% |
| 12 months | -68.9% |
| 12 months, with dividends | -68.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -76.1% | -37.9% |
| 5 years | -75.6% | -24.6% |
| 10 years | -96.9% | -29.3% |
Price by Year
Its best calendar year was 2025, when the price rose 77.0%, and its weakest was 2018, when it fell 76.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.28 | -64.3% |
| 2025 | $0.78 | +77.0% |
| 2024 | $0.44 | -60.8% |
| 2023 | $1.13 | +71.2% |
| 2022 | $0.66 | +17.9% |
| 2021 | $0.56 | -53.2% |
| 2020 | $1.20 | -25.2% |
| 2019 | $1.60 | -0.6% |
| 2018 | $1.61 | -76.6% |
| 2017 | $6.87 | +4.1% |
Trading Range
The price is 34.8% below its 50-day average of $0.31 and 53.9% below its 200-day average of $0.44.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.20 | |
| 52-week high | $0.84 | -75.9% |
| 52-week low | $0.17 | +19.2% |
| 50-day average | $0.31 | -34.8% |
| 200-day average | $0.44 | -53.9% |
Price Risk
Over 3 years, its largest fall from a peak was 85.4%.
| Measure | Value |
|---|---|
| 1-year beta | 0.58 |
| Largest fall, 1 year | -75.0% |
| Largest fall, 3 years | -85.4% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About XTNT
What is XTNT's 1-year price change?
Xtant Medical Holdings's price fell 68.9% over the past 12 months. With dividends included, the 12-month total return was -68.9%.
What is XTNT's 5-year price change?
Xtant Medical Holdings's month-end price fell 75.6% over the 5 years through Oct 2026, a compound annual decline of 24.6%. These figures leave out dividends.
What is XTNT's 52-week high and low?
Xtant Medical Holdings's 52-week high is $0.84 and its 52-week low is $0.17. Its latest price of $0.20 on Nov 17, 2026 is 75.9% below the high.
What is XTNT's beta?
Xtant Medical Holdings's 1-year beta against the S&P 500 is 0.58, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 75.0%.
Is the XTNT chart free?
Yes. Advanced Charting for XTNT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
XTNT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors